FDA designates BD's wide-ranging Alaris infusion pump recall as Class I

FDA
BD and its CareFusion subsidiary alerted users of potential device errors Feb. 4 and have been developing corrective software updates. (FDA)

BD is recalling hundreds of thousands of its Alaris infusion pumps and vital sign monitors due to multiple system faults, including software- and user-related issues. 

According to the FDA, the errors can lead to delays or interruptions in drug infusions or under- or over-dosing of medication at unexpected rates. The agency categorized the recall as Class I, its most serious, following 55 reported injuries and one death.

The recall affects about 774,000 devices in the U.S., distributed from as early as July 2004. This includes system PCs, pump modules and patient-controlled devices for managing pain. 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.
A BD Alaris PC Unit (FDA)

BD and its CareFusion subsidiary alerted users of potential device errors Feb. 4 and have been developing corrective software updates. The company said it would schedule updates with healthcare providers once they are available.

RELATED: BD to appoint new CEO as it finalizes C.R. Bard integration

The devices’ main software issues include system errors, low battery alarm failures and alarms sounding at an incorrect lower priority level as well as user-related errors related to the programming of custom medication concentration settings.

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.